IGC Pharma, Inc. Net Income Loss

• IGC Pharma, Inc. showed an increase of +45.2% in Net Income Loss from 2024 to 2025.
• This data is from IGC Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on June 27, 2025.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), IGC Pharma, Inc.'s Net Income Loss has grown by 64.8%.
• Historical annual values: Fiscal year 2025: -$7.12 million | Fiscal year 2024: -$13.00 million | Fiscal year 2023: -$11.51 million | Fiscal year 2022: -$15.02 million | Fiscal year 2021: -$8.81 million | Fiscal year 2020: -$7.32 million | Fiscal year 2019: -$4.10 million | Fiscal year 2018: -$1.79 million | Fiscal year 2017: -$1.87 million | Fiscal year 2016: -$2.81 million | Fiscal year 2015: -$4.61 million | Fiscal year 2014: -$3.02 million | Fiscal year 2013: -$2.25 million | Fiscal year 2012: -$7.75 million | Fiscal year 2011: -$20.24 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026